(S)-di-tert-butyl 2-(3-((S)-6-(benzylamino)-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentane-1,5-dioate | 1105575-34-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-di-tert-butyl 2-(3-((S)-6-(benzylamino)-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentane-1,5-dioate
• 英文别名: (S)-di-tert-butyl-2-(3-((S)-6-(benzylamino)-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentanedioate；ditert-butyl (2S)-2-[[(2S)-6-(benzylamino)-1-[(2-methylpropan-2-yl)oxy]-1-oxohexan-2-yl]carbamoylamino]pentanedioate
• CAS: 1105575-34-5
• 化学式: C₃₁H₅₁N₃O₇
• 分子量: 577.762
• InChiKey: MBNNPZBYRKHVIZ-ZEQRLZLVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  41
• 可旋转键数：
  20
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-di-tert-butyl 2-(3-((S)-6-(benzylamino)-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentane-1,5-dioate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以5 mg的产率得到
  参考文献：
  名称：

  A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer

  摘要：

  Prostate specific membrane antigen (PSMA) is a validated molecular marker for prostate cancer. A series of glutamate-urea (Glu-urea-X) heterodimeric inhibitors of PSMA were designed and synthesized where X = epsilon-N-(o-I, m-I, p-I, p-Br, o-C1, m-C1, p-C1, p-F, H)-benzyl-Lys and epsilon-(p-I, p-Br, p-C1, p-F, H)-phenylureido-Lys. The affinities for PSMA were determined by screening in a competitive binding assay. PSMA binding of the benzyllysine series was significantly affected by the nature of the halogen substituent (IC50 values, Cl < I = Br << F = H) and the ring position of the halogen atom (IC50 values, p-I < o-I << m-I). The halogen atom had little affect oil the binding affinity in the para substituted phenylureido-Lys series. Two lead iodine compounds were radiolabeled with I-123 and I-131 and demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.

  DOI：

  10.1021/jm800994j
• 作为产物：
  描述：

  在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 (S)-di-tert-butyl 2-(3-((S)-6-(benzylamino)-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentane-1,5-dioate
  参考文献：
  名称：

  A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer

  摘要：

  Prostate specific membrane antigen (PSMA) is a validated molecular marker for prostate cancer. A series of glutamate-urea (Glu-urea-X) heterodimeric inhibitors of PSMA were designed and synthesized where X = epsilon-N-(o-I, m-I, p-I, p-Br, o-C1, m-C1, p-C1, p-F, H)-benzyl-Lys and epsilon-(p-I, p-Br, p-C1, p-F, H)-phenylureido-Lys. The affinities for PSMA were determined by screening in a competitive binding assay. PSMA binding of the benzyllysine series was significantly affected by the nature of the halogen substituent (IC50 values, Cl < I = Br << F = H) and the ring position of the halogen atom (IC50 values, p-I < o-I << m-I). The halogen atom had little affect oil the binding affinity in the para substituted phenylureido-Lys series. Two lead iodine compounds were radiolabeled with I-123 and I-131 and demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.

  DOI：

  10.1021/jm800994j

文献信息

• Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them
  作者：Aleksei E. Machulkin、Radik R. Shafikov、Anastasia A. Uspenskaya、Stanislav A. Petrov、Anton P. Ber、Dmitry A. Skvortsov、Ekaterina A. Nimenko、Nikolay U. Zyk、Galina B. Smirnova、Vadim S. Pokrovsky、Maxim A. Abakumov、Irina V. Saltykova、Rauf T. Akhmirov、Anastasiia S. Garanina、Vladimir I. Polshakov、Oleg Y. Saveliev、Yan A. Ivanenkov、Anastasiya V. Aladinskaya、Alexander V. Finko、Emil U. Yamansarov、Olga O. Krasnovskaya、Alexander S. Erofeev、Petr V. Gorelkin、Olga A. Dontsova、Elena K. Beloglazkina、Nikolay V. Zyk、Elena S. Khazanova、Alexander G. Majouga

  DOI：10.1021/acs.jmedchem.0c01935

  日期：2021.4.22

  describe the design, synthesis, and biological evaluation of novel low-molecular PSMA ligands and conjugates with fluorescent dyes FAM-5, SulfoCy5, and SulfoCy7. In vitro evaluation of synthesized PSMA ligands on the activity of PSMA shows that the addition of aromatic amino acids into a linker structure leads to a significant increase in inhibition. The conjugates of the most potent ligand with FAM-5

  前列腺特异性膜抗原（PSMA），也称为谷氨酸羧肽酶II（GCPII），由于其在前列腺癌细胞中的过表达而成为抗肿瘤药物和诊断剂特异性递送的合适靶标。在当前的工作中，我们描述了新型的低分子PSMA配体和缀合物与荧光染料FAM-5，SulfoCy5和SulfoCy7的设计，合成和生物学评估。合成的PSMA配体对PSMA活性的体外评估表明，将芳香族氨基酸添加到接头结构中会导致抑制作用的显着增加。最有效的配体与FAM-5以及SulfoCy5的结合物在体外表现出对表达PSMA的肿瘤细胞的高亲和力。体内具有新型PSMA配体的PSMA-SulfoCy5和PSMA-SulfoCy7偶联物在Balb / c裸鼠的22Rv1异种移植物中的生物分布显示了表达PSMA的肿瘤的良好可视化。而且，缀合物PSMA-SulfoCy7证明不存在任何高达87.9 mg / kg的明确毒性。
• HETERODIMERS OF GLUTAMIC ACID
  申请人：Babich John W.

  公开号：US20080193381A1

  公开（公告）日：2008-08-14

  Compounds of Formula (Ia) wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Y is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2) p Z is H or C 1 -C 4 alkyl, R′ is H, C(O), S(O) 2 , C(O) 2 , a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 6 -C 12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

  化合物的化学式（Ia），其中R是C6-C12取代或未取代的芳基，C6-C12取代或未取代的杂环芳基，C1-C6取代或未取代的烷基或-NR′R′，Q是C（O），O，NR′，S，S（O）2，C（O）2（CH2）p，Y是C（O），O，NR′，S，S（O）2，C（O）2（ ）p，Z是H或C1-C4烷基，R′是H，C（O），S（O）2，C（O）2，C6-C12取代或未取代的芳基，C6-C12取代或未取代的杂环芳基或C1-C6取代或未取代的烷基，当取代时，芳基，杂环芳基和烷基取代为卤素，C6-C12杂环芳基，-NR′R′或COOZ，具有诊断和治疗特性，如治疗和管理前列腺癌和其他与NAALADase抑制相关的疾病。放射性标记可以通过连接到X氨基酸侧链的多种假体基团结构中。
• Heterodimers of Glutamic Acid
  申请人：Babich John W.

  公开号：US20120269726A1

  公开（公告）日：2012-10-25

  Compounds of Formula (Ia) wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Y is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Z is H or C 1 -C 4 alkyl, R′ is H, C(O), S(O) 2 , C(O) 2 , a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 1 -C 12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

  化合物的式子(Ia)，其中R是C6-C12取代或未取代芳基，C6-C12取代或未取代杂芳基，C1-C6取代或未取代烷基或—NR′R′，Q是C(O)，O，NR′，S，S(O)2，C(O)2(CH2)p，Y是C(O)，O，NR′，S，S(O)2，C(O)2( )p，Z是H或C1-C4烷基，R′是H，C(O)，S(O)2，C(O)2，C6-C12取代或未取代芳基，C6-C12取代或未取代杂芳基或C1-C6取代或未取代烷基，当取代时，芳基，杂芳基和烷基被卤素，C1-C12杂芳基，—NR′R′或COOZ取代，具有诊断和治疗性能，例如治疗和管理前列腺癌和其他与NAALADase抑制有关的疾病。可以通过连接到X氨基酸侧链的碳或杂原子连接处的各种假体团将放射性标记纳入结构中。
• Heterodimers of glutamic acid
  申请人：Molecular Insight Pharmaceuticals, Inc.

  公开号：US10640461B2

  公开（公告）日：2020-05-05

  Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R′ is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

  式（Ia）化合物 其中 R 是 C6-C12 取代或未取代的芳基、C6-C12 取代或未取代的杂芳基、C1-C6 取代或未取代的烷基或 -NR′R′、 Q 是 C(O)、O、NR′、S、S(O)2、C(O)2 (CH2)p Y 是 C(O)、O、NR′、S、S(O)2、C(O)2 ( )p Z 是 H 或 C1-C4 烷基、 R′ 是 H、C(O)、S(O)2、C(O)2、取代或未取代的 C6-C12 芳基、取代或未取代的 C6-C12 杂芳基或取代或未取代的 C1-C6 烷基，当芳基、杂芳基和烷基被卤素取代时、C6-C12杂芳基、-NR′R′或 COOZ，它们具有诊断和治疗特性，如治疗和控制前列腺癌以及与 NAALADase 抑制有关的其他疾病。放射性标记可通过碳原子或杂原子连接在 X 氨基酸侧链上的各种人工基团掺入结构中。
• Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery
  作者：Jan Tykvart、Jiří Schimer、Jitka Bařinková、Petr Pachl、Lenka Poštová-Slavětínská、Pavel Majer、Jan Konvalinka、Pavel Šácha

  DOI：10.1016/j.bmc.2014.05.061

  日期：2014.8

  Glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), is an established prostate cancer marker and is considered a promising target for specific anticancer drug delivery. Low-molecular-weight inhibitors of GCPII are advantageous specific ligands for this purpose. However, they must be modified with a linker to enable connection of the ligand with an imaging molecule, anticancer drug, and/or nanocarrier. Here, we describe a structure-activity relationship (SAR) study of GCPII inhibitors with linkers suitable for imaging and drug delivery. Structure-assisted inhibitor design and targeting of a specific GCPII exosite resulted in a 7-fold improvement in Ki value compared to the parent structure. X-ray structural analysis of the inhibitor series led to the identification of several inhibitor binding modes. We also optimized the length of the inhibitor linker for effective attachment to a biotin-binding molecule and showed that the optimized inhibitor could be used to target nanoparticles to cells expressing GCPII.